The science

A new generation
of snakebite treatment

Our oral combination therapy is designed to work where existing antivenom cannot: in the field, in the first hours after a bite.

The problem

Why existing antivenom falls short

Antivenom has barely changed since the 1890s. Its format limits where, when and for whom it works.

Clinical infrastructure only

Requires intravenous administration in a clinical setting, with cold-chain storage from factory to patient, making it unavailable across much of the world.

Species-specific

Limited efficacy across different snake species, so the wrong product is often ineffective against the actual bite.

Time-sensitive

Delays in treatment significantly reduce effectiveness in preventing death and disability.

Limited tissue protection

Limited ability to prevent or reverse the local tissue damage that causes lifelong disability.

Our approach

Oral, heat-stable, broad-spectrum

A heat-stable oral therapy can be stocked in clinics, pharmacies and field kits, and taken immediately after a bite. Broad-spectrum design means it is not limited to a single venom family.

Oral dosing, no injection or IV required
Heat-stable, no cold chain dependency
Designed for broad coverage across medically significant species
Tissue protection that preserves muscle function and limits lifelong disability

Green and white pharmaceutical capsules representing oral medication

Tissue protection

Protecting life and limb

While antivenom focuses on preventing death, it cannot reverse the tissue damage that causes lifelong disability. Our approach targets the mechanisms responsible for local tissue destruction.

450K People suffer permanent disabilities from snakebite each year

80% Of bite victims develop tissue damage that antivenom cannot address

Venom targets

Targeting the drivers of venom toxicity

Venom strikes fast. Within minutes, dozens of toxins attack blood vessels, destroy tissue, and shut down vital systems. Our therapy targets the key culprits before they can do their worst.

Prevalence

Found in 95% of snake venoms

What it does

Triggers massive inflammation and muscle breakdown, spreading damage throughout the body.

Our solution

We block this enzyme early to stop the inflammatory cascade before it can cause widespread tissue destruction.

Prevalence

Found in 80% of viper venoms

What it does

Shreds blood vessels and tissues, causing uncontrolled bleeding and devastating local damage.

Our solution

Our inhibitors protect blood vessel walls, preventing hemorrhage and preserving tissue integrity at the bite site.

Species in scope

Coverage of the most medically significant snakes

Our oral therapy is designed to cover the venom families responsible for the majority of global envenomings, starting with the four species that cause the highest burden in India.